JP2983295B2 - ベンゾピランおよびベンゾ縮合した化合物、それらの製造方法ならびにロイコトリエンｂ▲下４▼（ｌｔｂ▲下４▼）アンタゴニストとしてのそれらの使用 - Google Patents

ベンゾピランおよびベンゾ縮合した化合物、それらの製造方法ならびにロイコトリエンｂ▲下４▼（ｌｔｂ▲下４▼）アンタゴニストとしてのそれらの使用

Info

Publication number
JP2983295B2
JP2983295B2 JP8513057A JP51305796A JP2983295B2 JP 2983295 B2 JP2983295 B2 JP 2983295B2 JP 8513057 A JP8513057 A JP 8513057A JP 51305796 A JP51305796 A JP 51305796A JP 2983295 B2 JP2983295 B2 JP 2983295B2
Authority
JP
Japan
Prior art keywords
alkyl
group
hydroxy
perfluoroalkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP8513057A
Other languages
English (en)
Japanese (ja)
Other versions
JPH09512035A (ja
Inventor
ドムブロスキ，マーク・エイ
コック，ケヴィン
ピスコピオ，アンソニー・ダニエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of JPH09512035A publication Critical patent/JPH09512035A/ja
Application granted granted Critical
Publication of JP2983295B2 publication Critical patent/JP2983295B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/14—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with at least one hydroxy group on a condensed ring system containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP8513057A 1994-10-13 1995-05-26 ベンゾピランおよびベンゾ縮合した化合物、それらの製造方法ならびにロイコトリエンｂ▲下４▼（ｌｔｂ▲下４▼）アンタゴニストとしてのそれらの使用 Expired - Lifetime JP2983295B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US322,876 1989-03-14
US32287694A 1994-10-13 1994-10-13
US08/322,876 1994-10-13
PCT/IB1995/000401 WO1996011920A1 (en) 1994-10-13 1995-05-26 Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene b4 (ltb4) antagonists

Publications (2)

Publication Number Publication Date
JPH09512035A JPH09512035A (ja) 1997-12-02
JP2983295B2 true JP2983295B2 (ja) 1999-11-29

Family

ID=23256829

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8513057A Expired - Lifetime JP2983295B2 (ja) 1994-10-13 1995-05-26 ベンゾピランおよびベンゾ縮合した化合物、それらの製造方法ならびにロイコトリエンｂ▲下４▼（ｌｔｂ▲下４▼）アンタゴニストとしてのそれらの使用

Country Status (23)

Country Link
US (2) US6051601A (enExample)
EP (1) EP0785930A1 (enExample)
JP (1) JP2983295B2 (enExample)
KR (1) KR100232341B1 (enExample)
CN (1) CN1160399A (enExample)
AU (1) AU696890B2 (enExample)
BR (1) BR9504385A (enExample)
CA (1) CA2201742A1 (enExample)
CO (1) CO4480024A1 (enExample)
CZ (1) CZ111797A3 (enExample)
FI (1) FI971524A7 (enExample)
HU (1) HUT77515A (enExample)
IL (1) IL115529A0 (enExample)
MX (1) MX9702731A (enExample)
NO (1) NO971672L (enExample)
NZ (1) NZ285156A (enExample)
PE (1) PE10897A1 (enExample)
PL (1) PL319688A1 (enExample)
RU (1) RU2128655C1 (enExample)
TR (1) TR199501270A2 (enExample)
TW (1) TW304941B (enExample)
WO (1) WO1996011920A1 (enExample)
ZA (1) ZA958597B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK31399A3 (en) * 1996-09-16 2000-05-16 Pfizer Processes and intermediates for preparing substituted chromanol derivatives
CA2274908A1 (en) * 1996-12-13 1998-06-18 Eli Lilly And Company Leukotriene antagonists for cerebral focal stroke
IL128731A0 (en) * 1998-03-12 2000-01-31 Pfizer Prod Inc Method of preventing allograft rejection
EP0963755A3 (en) * 1998-04-16 2001-03-14 Pfizer Products Inc. Use of benzopyranes for preventing allograft rejection
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
MXPA03006876A (es) * 2001-01-30 2003-11-13 Pfizer Prod Inc Intermedios y procedimientos para preparar derivados de cromanol sustituido.
AU4239302A (en) * 2001-06-28 2003-01-02 Pfizer Products Inc. Benzoic acid substituted benzopyrans for the treatment of atherosclerosis
BR0311970A (pt) 2002-06-19 2005-03-29 Biovitrum Ab Novos compostos, seu uso e preparação
EP1773396A1 (en) * 2004-07-22 2007-04-18 Pharmacia Corporation Compositions for treatment of inflammation and pain using a combination of a cox-2 selective inhibitor and a ltb4 receptor antagonist
US7674822B2 (en) 2004-11-24 2010-03-09 Wyeth PTP1b inhibitors
CA2589363A1 (en) 2004-12-13 2006-06-22 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors
CA2600004A1 (en) 2005-02-25 2006-09-08 Eli Lilly And Company Spiro-heterocyclic chromans, thiochromans and dihydroquinolines
US7842713B2 (en) * 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
US7749995B2 (en) 2006-05-11 2010-07-06 Janssen Pharmaceutica Nv 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors
CA2651942A1 (en) 2006-05-11 2008-07-03 Janssen Pharmaceutica N.V. 1,2,3,4-tetrahydro-quinoline derivatives as cetp inhibitors
GEP20135793B (en) 2008-09-11 2013-03-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
WO2010103437A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Benzofuranyl derivatives used as glucokinase inhibitors
CA2864331C (en) 2012-02-14 2018-10-09 Children's Hospital Medical Center Use of small molecule inhibitors targeting the interaction between rac gtpase and p67(phox)
CN102920692A (zh) * 2012-10-25 2013-02-13 中国人民解放军第二军医大学 (e)-2-(1-羟基-4-环己酮)乙基咖啡酸酯在制备防治类风湿关节炎的药物中的应用
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
AR105911A1 (es) 2015-09-03 2017-11-22 Forma Therapeutics Inc Inhibidores de hdac8 bicíclicos fusionados [6,6]
WO2017095725A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists
US10370368B2 (en) 2015-11-30 2019-08-06 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
US10336733B2 (en) 2015-11-30 2019-07-02 Merk Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
WO2017095724A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists
US20190216790A1 (en) * 2016-10-13 2019-07-18 The Regents Of The University Of California Methods for Treating Pruritis
CN119700747B (zh) * 2025-02-26 2025-05-06 云南农业大学 苦杏碱醇a在制备防治骨质疏松症产品中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015067A1 (en) 1992-01-23 1993-08-05 Pfizer Inc. Benzopyran and related ltb4 antagonists
WO1993015066A1 (en) 1992-01-23 1993-08-05 Pfizer Inc. Benzopyran and related ltb4 antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU469247A3 (ru) * 1972-01-14 1975-04-30 Майлз Лабораториз Инк (Фирма) Способ получени производных хромона
US4565882A (en) * 1984-01-06 1986-01-21 G. D. Searle & Co. Substituted dihydrobenzopyran-2-carboxylates
CA1320490C (en) * 1987-01-12 1993-07-20 Darrel M. Gapinski Anti-inflammatory agents
US4889871A (en) * 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives
CA2019335C (en) * 1989-06-27 2000-08-01 Mitoshi Konno Phenylalkan (en)oic acids
US4996230A (en) * 1990-02-16 1991-02-26 Eli Lilly And Company Leukotriene antagonists
US5073562A (en) * 1990-05-10 1991-12-17 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof
US5051438A (en) * 1990-05-16 1991-09-24 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof, compositions and use
US5124350A (en) * 1990-06-28 1992-06-23 G. D. Searle & Co. Leukotriene b4 antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015067A1 (en) 1992-01-23 1993-08-05 Pfizer Inc. Benzopyran and related ltb4 antagonists
WO1993015066A1 (en) 1992-01-23 1993-08-05 Pfizer Inc. Benzopyran and related ltb4 antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｓｙｎｔｈｅｓｉｓ，１９８１，１，ｐ．５６−６０

Also Published As

Publication number Publication date
KR970706270A (ko) 1997-11-03
AU2416795A (en) 1996-05-06
PE10897A1 (es) 1997-04-21
NO971672L (no) 1997-06-11
US6051601A (en) 2000-04-18
TW304941B (enExample) 1997-05-11
US6133286A (en) 2000-10-17
ZA958597B (en) 1997-04-14
CA2201742A1 (en) 1996-04-25
CZ111797A3 (cs) 1998-07-15
NZ285156A (en) 1999-01-28
FI971524A0 (fi) 1997-04-11
PL319688A1 (en) 1997-08-18
JPH09512035A (ja) 1997-12-02
RU2128655C1 (ru) 1999-04-10
TR199501270A2 (tr) 1996-06-21
EP0785930A1 (en) 1997-07-30
WO1996011920A1 (en) 1996-04-25
FI971524A7 (fi) 1997-04-11
MX9702731A (es) 1997-06-28
BR9504385A (pt) 1997-05-27
CO4480024A1 (es) 1997-07-09
NO971672D0 (no) 1997-04-11
CN1160399A (zh) 1997-09-24
AU696890B2 (en) 1998-09-24
IL115529A0 (en) 1996-01-19
HUT77515A (hu) 1998-05-28
KR100232341B1 (ko) 2000-07-01

Similar Documents

Publication Publication Date Title
US6133286A (en) Tetrahydronaphthalene and tetrahydroquinoline compounds, their preparation and their use as leukotriene B4 (LTB4) antagonists
US5939452A (en) Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4' (LTB4) antagonists
CA2117349C (en) Benzopyrans and related ltb4 antagonists
MXPA97002731A (en) Benzopiran and benzo compounds fused, compositions that contain them and use of mis
EP0623123B1 (en) Benzopyran and related LTB4-antagonists
HK1000245B (en) Benzopyran and related ltb4-antagonists
KR100237528B1 (ko) 류코트리엔 비4 길항물질로서의 벤조피란 및 벤조-축합된 화합물